Triple-negative breast cancer is prevalent in BRCA1 mutation carriers, whereas estrogen receptor-positive, HER2-negative luminal breast cancer is more common in BRCA2 mutation carriers [3]. This evidence concerns the gene BRCA2 and breast cancer.